?:abstract
|
-
As of July 9, 2020, there were over 12 million confirmed cases of COVID-19 across the globe, with > 550,000 deaths Many European countries including Belgium, the United Kingdom, Italy, and Spain have had the highest numbers of fatalities per capita 1 This demonstrates the potential for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus to overwhelm even the most advanced healthcare systems despite extreme societal interventions Since its emergence, SARS-CoV-2 has disseminated across the globe, impacting the structure of global societies, infrastructure and economies Patients with alopecia are a diverse group who, for various indications, are prescribed a number of anti-microbials and anti-androgen treatments in addition to immunomodulatory therapies such as hydroxychloroquine, oral corticosteroids and a range of broad immunosuppressants These drugs are being scrutinized for their capacity to potentially impact SARS-CoV-2 outcomes We examine these treatments and highlight the critical role that patient registries will play in generating real-world evidence to assess their impact on COVID-19 outcomes
|